Dr. Madigan has a strong scientific background and over 25 years of experience in corporate financing, operations, business development and M&A. Dr. Madigan is currently a Managing Partner with Avalon BioVentures. Dr Madigan founded three companies from prior Avalon funds and currently serves as CEO of Ankasa Regenerative Therapeutics (Avalon X) and Nerio Therapeutics (Avalon XI) and President and CBO of Enlaza Therapeutics (Avalon XI). Previously, Dr. Madigan was the CEO of Calporta Therapeutics (Avalon X) which was acquired by Merck in November 2019 for up to $576M.

Dr. Madigan was also a founding member of various Avalon Ventures portfolio companies from earlier funds, including Ambit Biosciences (IPO, acquired by Daiichi Sankyo), Xenopharm (acquired by Deltagen) and X-Ceptor Therapeutics (acquired by Exelixis). He was a founder and the CEO of Strategic Enzyme Applications, a private company established in partnership with Monsanto. Dr. Madigan was also a founder and VP Corporate Development for BioVerdant, a venture-backed clean technology company.

Dr. Madigan performed his post-doctoral training at The Salk Institute for Biological Studies. He received his Ph.D. in Genetics and his B.S. in Biochemistry from The State University of New York at Stony Brook where, as a graduate student, he was awarded the Abrahams Memorial Award for outstanding potential for basic research.